Injectable Drug Delivery conference 2018

SMi Group16 - 17 May 2018, London, UK.
The SMi Group are thrilled to present the launch of Injectable Drug Delivery Conference 2018. The event is taking place in central London on 16th and 17th May 2018, with two pre-conference workshops occurring on 15th May 2018.

The Global Injectable Drug Delivery Market is expected to reach $789.7 billion USD by 2024, with a compound annual growth rate (CAGR) of 11.5% during the period of 2017 to 2024, according to Research Markets Reports. Therefore, this conference will aim to discuss the key developments in this field and the latest technological advancements.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2018:

  • Jean-René Authelin, Global Head, Pharmaceutical Engineering, Sanofi
  • Joel Richard, Senior Vice President, Peptides Development, Ipsen

Featured speakers:

  • Anand Subramony, Vice President, Novel Product Technologies, MedImmune
  • Mostafa Nakach, Head of Pharmaceutical Engineering, Sanofi
  • Maxime Gaillot, Senior Device Engineer, Roche
  • Pierre Goldbach, Senior Principal Scientist, Late-Stage Pharmaceutical and Processing Development, F. Hoffmann-La Roche AG
  • Fie Falck Larsen, Senior Usability Engineer, Injection Devices, Global Research and Development, LEO Pharma
  • Francesco Malavasi, Medical Device Quality Device Risk Manager, Novartis

Featured highlights:

  • Review device designs for a future portfolio
  • Explore risk management options for combination products
  • Hear how companies are tackling compatibility challenges of biologics with high volume injectors
  • Learn how vial-based novel delivery technologies can overcome complex dosing regiments
  • Discover how nanosystems can help address present and future challenges in injectable peptide delivery

View the full agenda online.

Early-Bird Rates

  • Book by 31st January and save £400
  • Book by 28th February and save £200
  • Book by 29th March and save £100

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/uk/injectable-drug-delivery

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...